Reliance-backed genomics company is pursuing US FDA approval for CancerSpot and aims to cut its price in India to below ₹10,000 over the next two to three years. Strand Life Sciences, a subsidiary of Reliance Industries, is looking to expand its blood-based cancer screening test, CancerSpot, into overseas markets, with the US, Southeast Asia and the Middle East among the regions it is targeting.